Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia Plans to Submit MAA for Pridopidine in Huntington’s
Details : TV-7820 (pridopidine) is an oral, highly selective and potent investigational S1R agonist, which is being evaluated as a potential treatment for Huntington’s disease.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia Announces Clinical Data Supporting Plans for Global Phase 3 Study in ALS
Details : Pridopidine is an investigational oral, small molecule, highly selective and potent Sigma-1 Receptor (S1R) agonist which is being evaluated as a potential treatment for ALS and Huntington’s disease.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2024
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
Details : Pridopidine is an oral, highly selective S1R agonist which stimulates multiple cellular pathways, including autophagy, which are essential to neuronal function and survival, and may lead to neuroprotective effects.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pridopidine is currently being assessed in the HEALEY ALS Platform Trial in the U.S., the first for ALS. The pridopidine regimen enrolled its first participant in January 2021 and is on track to generate results in H2 2022.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2021
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prilenia Receives Positive EMA Opinion on Orphan Drug Designation for Pridopidine in Als
Details : Pridopidine is a potent and selective Sigma-1 receptor (S1R) agonist, currently being assessed in the HEALEY ALS Platform trial in the US; a multi-center, multi-regimen clinical study evaluating the safety and efficacy of investigational products for the...
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2021
Lead Product(s) : Pridopidine
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable